Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3′s diagnostic test, and focused on Power3′s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3′s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3′s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3′s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of Power3, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
The LGL Group, Inc. (NYSE Amex:LGL) has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). If declared effective by the SEC, the shelf registration statement will permit the Company to offer and sell from time to time in one or more public offerings up to $13.5 million aggregate dollar amount of any combination of common stock, debt securities, warrants, or units. The specific terms of any such future offerings will be established by the Company at the time of each offering, subject to market conditions, and will be described in detail in a prospectus supplement that will be filed with the SEC at the time of the offering.
The LGL Group, Inc., through its wholly-owned subsidiary MtronPTI, manufactures and markets highly-engineered electronic components used to control the frequency or timing of signals in electronic circuits. These devices are used extensively in infrastructure equipment for the telecommunications and network equipment industries. They are also used in electronic systems for military applications, avionics, earth-orbiting satellites, medical devices, instrumentation, industrial devices and global positioning systems. The Company has operations in Orlando, Florida, Yankton, South Dakota and Noida, India. MtronPTI also has sales offices in Hong Kong and Shanghai, China.
LHC Group, Inc. (Nasdaq:LHCG), a national provider of home health and hospice services, has acquired 100% of the assets of Haggin Home Health from The James B. Haggin Memorial Hospital in Harrodsburg, Kentucky. The newly acquired agency will operate under the name of Lifeline Health Care of Harrodsburg.
The primary service area of this acquisition includes Mercer County in Kentucky, a Certificate of Need (CON) state. The estimated population of the service area is 22,000, with almost 15% over the age of 65. Annual net revenue for the Harrodsburg, Kentucky agency in 2009 was approximately $400,000. This acquisition is not expected to add materially to LHC Group’s earnings in 2010.
LHC Group, Inc. is a national provider of home health and hospice services, providing quality, cost-effective healthcare to patients within the comfort and privacy of their home or place of residence. LHC Group provides a comprehensive array of post-acute healthcare services through home health and hospice locations in its home-based division and long-term acute care hospitals in its facility-based division.
Liberty Global, Inc. (NASDAQ: LBTYA) (NASDAQ: LBTYB) (NASDAQ: LBTYK), will appoint Diederik Karsten to the newly created position of Managing Director, European Broadband Operations for Liberty Global effective January 1, 2011. Diederik Karsten will succeed Gene Musselman who has decided to retire, effective at the end of this year, from the position of President and COO of UPC Broadband after nearly 20 years with Liberty Global and over 35 years in the cable business. Gene Musselman will continue to assist Liberty Global in Germany as CEO of Unitymedia, and will serve as special advisor to the CEO of Liberty Global on various strategic and operating initiatives.
Liberty Global is the leading international cable operator offering advanced video, voice and broadband internet services to connect its customers to the world of entertainment, communications and information. As of June 30, 2010, Liberty Global operated state-of-the-art networks serving 18 million customers across 14 countries principally located in Europe, Chile and Australia. Liberty Global�s operations also include significant programming businesses such as Chellomedia in Europe.
No comments:
Post a Comment